Alembic Pharma gets tentative USFDA nod for generic cancer drug; may secure 180-day exclusivity

With the latest approval, Alembic Pharma’s cumulative USFDA tally stands at 241 ANDA approvals, comprising 221 final approvals and 20 tentative approvals.

Leave a Reply

Your email address will not be published. Required fields are marked *